



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

## Operations Office

---

Date: July 13, 2007  
To: NCCTG Primary Clinical Research Associates  
From: Laura Denton, Protocol Development Coordinator  
Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR<sup>®</sup> Depot) for Symptomatic Ascites in Cancer Patients

The Blood Specimen Submission Form has been revised to add “with ovarian cancer.” The End of Active Treatment Form has been revised to delete the \* by 4 disease progression and corresponding footnote. Also, the Patient Questionnaire Booklet Compliance Form is newly added.

If you have any questions, please feel free to contact me at 507/538-1802.

Thank you.